减少毛细支气管炎患儿沙丁胺醇使用
该研究旨在通过多学科团队重新设计临床路径和医嘱集,降低急诊和住院毛细支气管炎患儿的沙丁胺醇使用比例。研究期间纳入3834例急诊就诊和1119例住院患儿,急诊沙丁胺醇使用率从43%降至20%,住院从18%降至11%,且 admission rate、住院时间和再就诊率保持不变。
要点
- 多学科团队重新设计临床路径和医嘱集可显著减少沙丁胺醇使用。
- 急诊沙丁胺醇使用率从43%降至20%,住院从18%降至11%。
- 干预未影响 admission rate、住院时间和再就诊率。
核心结论
- 通过多学科团队重新设计毛细支气管炎临床路径和医嘱集,在大规模儿童医院显著减少了沙丁胺醇使用,且未影响其他结局指标。
研究设计与样本
- 研究为质量改进项目,旨在将急诊毛细支气管炎患儿沙丁胺醇使用比例从43%降至<35%,住院从18%降至<10%。
- 研究期间纳入3834例急诊就诊和1119例住院患儿。
主要发现
- 急诊沙丁胺醇使用率从43%降至20%,低于上一年建立的<3 SD控制限,达到特殊原因变异统计阈值。
- 住院沙丁胺醇使用率从18%降至11%,也达到特殊原因变异并接近目标。
- 两个部门的变化在整个毛细支气管炎季节持续,且 admission rate、住院时间和再就诊率保持不变。
关键数值与推荐
- 急诊沙丁胺醇使用率目标从43%降至<35%,实际降至20%。
- 住院沙丁胺醇使用率目标从18%降至<10%,实际降至11%。
临床怎么用
- 临床可参考该多学科质量改进模式,通过路径和医嘱集调整及教育反馈减少不推荐药物的使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In 2014, the American Academy of Pediatrics published bronchiolitis guidelines recommending against the use of bronchodilators. For the winter of 2015 to 2016, we aimed to reduce the proportion of emergency department patients with bronchiolitis receiving albuterol from 43% (previous winter rate) to <35% and from 18% (previous winter rate) to <10% in the inpatient setting. METHODS: A team identified key drivers of albuterol use and potential interventions. We implemented changes to our pathway and the associated order set recommending against routine albuterol use and designed education to accompany the pathway changes. We monitored albuterol use through weekly automated data extraction and reported results back to clinicians. We measured admission rate, length of stay, and revisit rate as balancing measures for the intervention. RESULTS: The study period included 3834 emergency department visits and 1119 inpatient hospitalizations. In the emergency department, albuterol use in children with bronchiolitis declined from 43% to 20% and was <3 SD control limits established in the previous year, meeting statistical thresholds for special cause variation. Inpatient albuterol use decreased from 18% to 11% of patients, also achieving special cause variation and approaching our goal. The changes in both departments were sustained through the entire bronchiolitis season, and admission rate, length of stay, and revisit rates remained unchanged. CONCLUSIONS: Using a multidisciplinary group that redesigned a clinical pathway and order sets for bronchiolitis, we substantially reduced albuterol use at a large children's hospital without impacting other outcome measures.
引用
- Dunn M, Muthu N, Burlingame CC, et al. Reducing Albuterol Use in Children With Bronchiolitis. Pediatrics. 2019. PMID: 31810996. doi:10.1542/peds.2019-0306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。